Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus FORTAZ.
CEFACLOR vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 8 hours
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateWarfarin + Cefaclor
"Warfarin may increase the anticoagulant activities of Cefaclor."
Clinical Note
moderatePhenprocoumon + Cefaclor
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefaclor."